| Trial ID: | L6713 |
| Source ID: | NCT00475371
|
| Associated Drug: |
Mkc253 Inhalation Powder
|
| Title: |
A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Healthy Males
|
| Interventions: |
DRUG: MKC253 Inhalation Powder
|
| Outcome Measures: |
Primary: Determine the safety and tolerability of ascending doses of MKC253 Inhalation Powder, 2 weeks | Secondary: Incidence of pulmonary and other AEs, 2 weeks|Pharmacokinetic (PK) parameters of plasma GLP-1, 2 weeks
|
| Sponsor/Collaborators: |
Sponsor: Mannkind Corporation
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
26
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-04
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2012-06-14
|
| Locations: |
University Medical Centre Groningen, Zuidlaren, 9470 AE, Netherlands
|
| URL: |
https://clinicaltrials.gov/show/NCT00475371
|
